CUV 1.02% $14.59 clinuvel pharmaceuticals limited

Ann: Chair Elect Letter, page-8

  1. 594 Posts.
    lightbulb Created with Sketch. 281
    Has this become a lifestyle company for the CEO and senior management? The new chairman ( appointed by the CEO) seems only interested in retaining the poorly performing management team. Negative return over 5 years, in what should have been the most exciting period ( post FDA approval). Surely it is time for a change. Enough of the lies and false promises.

    looking forward to phi/parvismelanotide results Cy 23 as promised
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.